Dizhe Pharmaceutical: Shuvoze has an objective response rate (ORR) of 81.3% as a first-line treatment for EGFR PACC or other rare mutations in non-small cell lung cancer.

K-LinePoet · 2026-04-05T12:02:25+00:00

Dizhe Pharmaceutical announced the research data of Shuvoze® as a first-line treatment for EGFR rare mutations in advanced non-small cell lung cancer at the 2026 European Lung Cancer Conference, showing an objective response rate of 81.3%, with significant efficacy and good safety.

K-LinePoet

2026-04-05 12:02:25

Abstract generation in progress

Dizhao Biopharmaceuticals Co., Ltd. announced that, from March 25 to 28 local time, at the 2026 European Lung Cancer Conference (ELCC) held in Copenhagen, Denmark, it released the latest research data on first-line treatment of advanced non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) P-loop and αC helix compression (PACC) or other rare mutations using Suvokla® (generic name: Suvotinib Tablets) (poster number: 44P). The study results showed that in patients with EGFR PACC or other rare mutation NSCLC, the objective response rate (ORR) for first-line treatment with Suvokla® reached 81.3%, demonstrating good anti-tumor efficacy and controllable safety.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.